AbbVie lowered its 2026 adjusted EPS guidance to $13.76 to $13.96 on Oct. 5, reflecting $1.25 billion of acquired IPR&D and milestone expense.
Altria yields 6.2% against AbbVie’s 2.6%, while AbbVie raised its dividend faster from fiscal 2020 to fiscal 2025: 6.6% a year against Altria’s 4.1%.
AbbVie’s dividend used 66% of free cash flow over the 12 months to June 30, 2026, against 78% for Altria.
AbbVie’s payout ratio climbed from 41% in fiscal 2022 to 65% in fiscal 2025, while Altria’s stayed between 75% and 82% from fiscal 2021 to fiscal 2025.
AbbVie (ABBV:NYSE) lowered its 2026 earnings guidance in a filing on Oct. 5. Adjusted EPS is now expected at $13.76 to $13.96, down from $13.87 to $14.07, reflecting $1.25 billion of acquired IPR&D and milestones expense for the year.
That’s the price of buying its next pipeline. Altria Group (MO:NYSE) offers the opposite trade. In July, it narrowed its 2026 outlook to 3.5% to 5.5% adjusted EPS growth, and its yield is more than twice AbbVie’s.
If you’re putting $10,000 to work for the next decade, which one do you hold?
Source: TIKR, Oct. 9, 2026.
AbbVie’s new drugs are carrying the load
In the second quarter of 2026, Skyrizi, Rinvoq, and AbbVie’s neuroscience drugs each grew more than 20%. Those drugs are outrunning Humira, whose global sales fell 36.1% operationally in the quarter as biosimilars took share.
The dividend used 66% of free cash flow over the 12 months to June 30, 2026. That’s a well-covered figure on its own, but the trend is moving the wrong way…
AbbVie (ABBV): free cash flow vs. common dividends paid, $ billions, fiscal 2016–2025 (TIKR)
AbbVie’s free cash flow peaked at $24.3 billion in fiscal 2022 and came in at $17.8 billion in fiscal 2025, while dividends paid rose from $10.0 billion to $11.7 billion over the same stretch. Squeezed from both sides, the payout ratio climbed from 41% to 65%.
The cushion behind the dividend has shrunk every year since fiscal 2022, and debt adds to the risk. Net debt is 2.06x EBITDA, and CFO Scott Reents said AbbVie is “committed to achieving a net leverage ratio of 2x within 2 to 3 years following the deal close” on its planned Apogee acquisition.
Today, a 2.6% yield means $10,000 pays $260 a year. Grow that at 6.6% annually, and it becomes about $461 in year 10, a 4.6% yield on your original cash, and about $3,519 over the decade. On its own, that’s not a big check, so you’d also be counting on capital appreciation.
Altria’s slow, steady machine
Altria is almost the mirror image of AbbVie, with steady cash flow on one hand and a core business that’s slowly shrinking on the other.
Altria’s domestic cigarette shipments are falling right along with the rest of the industry, and nicotine pouches are where the growth is, led by the national rollout of on! PLUS. Across the whole business, revenue net of excise taxes still rose 1.2% in the second quarter of 2026, and adjusted EPS rose 2.8% to $1.48.
That’s slow growth, but the dividend mostly needs steady cash…
Altria Group (MO): free cash flow vs. common dividends paid, $ billions, fiscal 2016–2025 (TIKR)
Free cash flow rose from $8.15 billion in fiscal 2020 to $9.07 billion in fiscal 2025, and dividends paid rose from $6.29 billion to $6.96 billion. The payout ratio stayed between 75% and 82% every year from fiscal 2021 to fiscal 2025. At 78% over the 12 months to June 30, 2026, it’s high, but in line with the past five years.
At a 6.2% yield, $10,000 pays $620 a year today. At 4.1% annual growth, that becomes about $891 in year 10, an 8.9% yield on your original cash, and about $7,484 over the decade. The main risk is that cigarette volumes keep falling faster than pouches can make up the difference.
So which dividend wins?
I’d hold Altria for the next 10 years.
The income gap is too wide to ignore. Over the decade, $10,000 in Altria pays about $7,484, against about $3,519 for AbbVie. At these rates, AbbVie’s yearly income wouldn’t pass Altria’s for more than 30 years.
Altria’s pace also looks like one it can keep up. Its payout ratio has stayed in the same range for five years, and its 3.5% to 5.5% EPS growth guidance for 2026 lines up with 4.1% annual raises. Altria also carries less debt and trades at 12.4x forward earnings, against 18.0x for AbbVie.
AbbVie’s dividend is still safe, and its growth drugs are real. A 66% payout ratio leaves more room than Altria’s 78%, and AbbVie has raised its dividend faster. The trouble is that the room has been shrinking since fiscal 2022 while debt is set to rise, so over 10 years Altria simply pays you more.
Of course, management says industry cigarette declines have moderated for four quarters in a row. If that reverses, Altria’s raises get harder to fund.
So what is Altria stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Altria could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Micron (NASDAQ: MU) has been a great stock to own in 2026, but I’m betting that it goes even higher by 2030. In fact, it could transform a $10,000 investment made today into a $42,000 position by then — and that’s on the conservative side of my estimated range. That may seem unrealistic, but the
Palantir (PLTR) was breaking records earlier this week. Now its breakout has reversed, with the stock heading toward correction territory. Shares fell roughly 7% Friday, erasing about $34 billion in market value. The closing number to watch is $188.15. Below that, Palantir would finish more than 10% beneath its Oct. 9 record close, confirming a
Quick Read AAPL turned $10,000 into $127,753 over the last decade, but its $4.96T market cap limits the next 5-year base case to roughly $16,271. iPhone 17 revenue surged 22% to $54B and Services hit $30.7B, powering a record $109B June quarter for Apple. Valuation at 39x earnings, shrinking gross margins, and iPhone 18 Pro
CoreWeave (CRWV) sprang a bear trap Thursday. Now another sell-off is testing whether the bulls can hold their ground. The AI cloud provider’s shares are falling Friday after staging a dramatic reversal the previous session. Shares briefly broke below their summer floor near $60 on Thursday, sank to $59.51, then climbed to $69.76 — a
What happened: Moderna (MRNA) stock tanked 9% on Friday. What’s behind the move: The biotech giant sank as investors took profits and Wall Street grew cautious on the stock’s blistering rally of more than 600% year to date. Goldman Sachs (GS) raised its target on the stock to $137 from $120 on Thursday while maintaining a Neutral
It’s no secret that stocks connected to the AI industry have been some of the market’s top performers over the past year, but there are still a few that remain relatively under the radar. Silicon Motion Technology (NASDAQ: SIMO) is one of them. It produces NAND flash controllers, which are vital for AI infrastructure. That’s
Harris Oakmark recently released its third-quarter 2026 investor letter for its “Oakmark Global Select Fund”. It is a non-diversified fund that focuses on long-term capital appreciation by investing in common stocks of U.S. and non-U.S. companies. The letter can be downloaded here. The Fund (Investor Class) returned 5.14% for the quarter, surpassing the MSCI World
In recent years, artificial intelligence (AI) stocks soared in the triple and quadruple digits, leading the S&P 500 higher. Investors rushed to get in on the next big tech growth story, a technology with the potential to transform how many things are done and, as a result, fuel significant gains in corporate earnings. Companies such
Japanese financials suddenly sit in the spotlight as the Bank of Japan hints at tighter policy and questions mount over how far inflation might run. Lending, insurance and balance sheets all feel different when rates move, and that can shift the story for specific stocks in a hurry. This article explains how that backdrop relates
For much of 2026, a rough stretch in the stock market has been a double whammy. Investors have had to contend not only with stock losses, but bonds selling off, too. The dynamic upended the safety trade of rotating out of stocks and into Treasurys. It’s hard to diversify when there’s nowhere to hide. Why
Like groceries, gasoline, housing, and pretty much everything else, the cost of power has soared since 2021. The average U.S. household’s utility bill now stands at $147 per month, according to Electricrates.org, and that’s just for electricity. Adding other utilities like water and gas raises this average up to $470 per month. People are being
Margin loans hit three-month high as market participants question effectiveness of regulators’ response Lee Eog-weon, chairman of the Financial Services Commission, answers questions during a plenary session of the National Assembly’s Political Affairs Committee in Yeouido, Seoul, in September. (The Korea Herald) As South Korea’s stock market continues to swing sharply between steep losses and
RKLB dropped as Neutron’s debut slipped to 2027, while ARK bought 168,633 shares worth about $9.32 million. ASTS fell amid divided analyst calls over competition from SpaceX and uncertainty about its next satellite launch. RDW announced $13.8 million in National Guard drone orders and an upcoming ISS solar-array delivery. SpaceX (SPCX) weathered this week’s space-stock
Proceeds could fund bitcoin purchases, investments, acquisitions and ASST or SATA share repurchases. CEO Matt Cole called criticism of ASST’s five-year performance “meaningless,” saying Strive had outperformed bitcoin since its reverse merger. SATS carries a $15 annual dividend per share, offering a 16.67% yield at the offer price if paid fully. Shares of Strive, Inc.
Micron (NASDAQ: MU) has been one of the biggest winners of the AI era. Over the last year, the stock is up roughly 400%, and over the last three years, the stock has jumped 1,250%. Like other memory stocks, Micron has benefited from a shortage in memory chips, which has driven up prices and sent
Tesla is hours away from revealing its long delayed next generation Roadster, a halo sports EV teased with possible brief flight and SpaceX designed cold gas thrusters, at a livestreamed event from Texas. The Roadster is positioned less as a volume product and more as a showcase of Tesla’s engineering, AI and high end performance
Fundstrat’s Mark Newton says investors should buy the tech dip while staying diversified. Artificial intelligence (AI) cloud provider CoreWeave, down 15% at one point, still faces higher bond yields over its debt. The equal-weight S&P 500, which gives every company the same weight, fell about 6%. The headline S&P 500, by contrast, hit a record
S&P 500 record high stock market cover. Photo by BeInCrypto CNBC host Jim Cramer backed Reddit (RDDT) and Rocket Lab (RKLB) but passed on SiTime (SITM) on Thursday’s “Mad Money,” favoring stocks that have fallen over those priced for growth while interest rates climb. The picks span social media, rockets, refiners and chips, yet one
Image from Pixabay Applied Materials (AMAT) stock has fallen 17.6% since its close on October 5, 2026. That is short of the 20% falls studied below, so the history is a rough guide rather than a close match. Investors are betting the semiconductor equipment maker will repeat its history of share price rebounds and that
Michael Saylor’s Bitcoin giant could lose its place in major global stock indexes, potentially forcing investment funds to sell shares even if they still believe in the company. On Thursday, MSCI approved new rules to remove companies that behave more like investment vehicles than operating businesses. Its earlier simulation identified Strategy, formerly MicroStrategy, and Japan’s
